Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 3, 2004, Pages 1165-1173

  De Medina, Philippe ^a   Payré, Bruno L ^a,c   Bernad, José ^b   Bosser, Isabelle ^d   Pipy, Bernard ^b   Silvente Poirot, Sandrine ^a   Favre, Gilles ^a   Faye, Jean Charles ^a   Poirot, Marc ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CHU RANGUEIL   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d Affichem ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (4 BENZYLPHENOXY)ETHYL] N PYRROLIDINE; 11 [4 (2 DIMETHYLAMINOETHOXY)PHENYL]ESTRADIOL; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 3 DECYLDIMETHYLSILYL N [2 (4 METHYLPHENYL) 1 PHENYLETHYL]PROPIONAMIDE; 4 HYDROXYTAMOXIFEN; [2 (4 BENZYLPHENOXY)ETHYL] N,N DIMETHYLAMINE; ANTIESTROGEN; BENZOTHIOPHENE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; DIETHYLSTILBESTROL; DIPHENYLETHANE; DIPHENYLMETHANE DERIVATIVE; ESTRA 1,3,5(10) TRIENE; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; LIGAND; LOW DENSITY LIPOPROTEIN; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NITROMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STILBENE DERIVATIVE; STILBENE DIETHYLSTILBESTROL; STILBENE TRIPHENYLETHYLENE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CATALYSIS; CHOLESTEROL ESTERIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; FOAM CELL; LIPOGENESIS; LIVER MICROSOME; MACROPHAGE; MALE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL ESTERS; ESTERIFICATION; ESTROGEN ANTAGONISTS; FOAM CELLS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; STEROL O-ACYLTRANSFERASE; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

EID: 1342329734     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.060426     Document Type: Article

References (36)

1. Argmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM, and Huff MW (2001) Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. Arterioscler Thromb Vasc Biol 21:2011-2018.
2. Basu SK, Goldstein JL, Anderson GW, and Brown MS (1976) Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci USA 73:3178-3182.
3. Bligh EG and Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Brown MS and Goldstein JL (1983) Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-261.
6. Brown MS, Ho YK, and Goldstein JL (1980) The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem 255:9344-9352.
7. Chailleux C, Poirot M, Mesange F, Bayard F, and Faye JC (1994) Characterization of the membranous antiestrogen binding protein. I. Partial purification of the protein in its active state. J Recept Res 14:23-35.
8. Chang TY, Chang CC, and Cheng D (1997) Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Biochem 66:613-638.
9. Chang TY, Chang CC, Lin S, Yu C, Li BL, and Miyazaki A (2001) Roles of acylcoenzyme A:cholesterol acyltransferase-1 and -2. Curr Opin Lipidol 12:289-296.
10. Clader JW, Berger JG, Burrier RE, Davis HR, Domalski M, Dugar S, Kogan TP, Salisbury B, and Vaccaro W (1995) Substituted (1,2-diarylethyl)amide acyl-CoA: cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity. J Med Chem 38:1600-1607.
11. Clarke SC, Schofield PM, Grace AA, Metcalfe JC, and Kirschenlohr HL (2001) Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 103:1497-1502.
12. Delsing DJ, Offerman EH, van Duyvenvoorde W, van Der Boom H, de Wit EC, Gijbels MJ, van Der Laarse A, Jukema JW, Havekes LM, and Princen HM (2001) Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 103:1778-1786.
13. Dugar S, Clader JW, Burrier RE, and Kogan TP (1993) N-Oleyl-1,2,3,4-Tetraisoquinolines as conformationally restricted inhibitors of acyl-CoA: cholesterol acyl transferase (ACAT). Bioorg Med Chem Lett 3:571-576.
14. Etienne MC, Milano G, Fischel JL, Frenay M, Francois E, Fonnento JL, Gioanni J, and Namer M (1989) Tamoxifen metabolism: pharmacokinetic and in vitro study. Br J Cancer 60:30-35.
15. Grainger DJ, Witchell CM, and Metcalfe JC (1995) Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med 1:1067-1073.
16. Heider JG, Pickens CE, and Kelly LA (1983) Role of acyl CoA:cholesterol acyltransferase in cholesterol absorption and its inhibition by 57-118 in the rabbit. J Lipid Res 24:1127-1134.
17. Heinonen TM (2002) Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis? Curr Atheroscler Rep 4:65-70.
18. Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205-213.
19. Kusunoki J, Hansoty DK, Aragane K, Fallon JT, Badimon JJ, and Fisher EA (2001) Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 103:2604-2609.
20. Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, and Grainger DJ (1996) Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem 271:31367-31371.
21. Matsuda K (1994) ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms. Med Res Rev 14:271-305.
22. McDonald CC, Alexander FE, Whyte BW, Forrest AP, and Stewart HJ (1995) Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. Br Med J 311:977-980.
23. McDonald CC and Stewart HJ (1991) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. Br Med J 303:435-437.
24. Peng S, Guo W, Morrisett JD, Johnstone MT, and Hamilton JA (2000) Quantification of cholesteryl esters in human and rabbit atherosclerotic plaques by magic-angle spinning (13)C-NMR. Arterioscler Thromb Vasc Biol 20:2682-2688.
25. Poirot M, De Medina P, Delarue F, Perie JJ, Klaebe A, and Faye JC (2000) Synthesis, binding and structure-affinity studies of new ligands for the microsomal antiestrogen binding site (AEBS). Bioorg Med Chem 8:2007-2016.
26. Pollaud-Cherion C, Vandaele J, Quartulli F, Seguelas MH, Decerprit J, and Pipy B (1998) Involvement of calcium and arachidonate metabolism in acetylated-low-density-lipoprotein-stimulated tumor-necrosis-factor-alpha production by rat peritoneal macrophages. Eur J Biochem 253:345-353.
27. Poumay Y and Ronveaux-Dupal MF (1985) Rapid preparative isolation of concentrated low density lipoproteins and of lipoprotein-deficient serum using vertical rotor gradient ultracentrifugation. J Lipid Res 26:1476-1480.
28. Reckless J, Metcalfe JC, and Grainger DJ (1997) Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation 95:1542-1548.
29. Ross AC, Go KJ, Heider JG, and Rothblat GH (1984) Selective inhibition of acyl coenzyme A:cholesterol acyltransferase by compound 58-035. J Biol Chem 259:815-819.
30. Rutqvist LE and Mattsson A (1993) Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406.
31. Sliskovic DR, Picard JA, and Krause BR (2002) ACAT inhibitors: the search for a novel and effective treatment of hypercholesterolemia and atherosclerosis. Prog Med Chem 39:121-171.
32. Stahl E (1969) Thin Layer Chromatography. Springer-Verlag, New York.
33. Tabas I (2002) Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J Clin Investig 110:905-911.
34. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, and Fine RL (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811-1816.
35. Warner GJ, Stoudt G, Bamberger M, Johnson WJ, and Rothblat GH (1995) Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol. J Biol Chem 270:5772-5778.
36. Williams JK, Wagner JD, Li Z, Golden DL, and Adams MR (1997) Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol 17:403-408.